Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04078152 · ClinicalTrials.gov registry record · Phase 4
Durvalumab Long-Term Safety and Efficacy Study
A Phase 4 study of Solid Tumor, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT04078152: Completed Phase 4 study of Solid Tumor, sponsored by AstraZeneca.
NCT04078152 is a Phase 4 study of Solid Tumor that has completed, run by AstraZeneca. The registered enrollment target is 163 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04078152, a Phase 4 study of Solid Tumor, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
Primary Outcome
An AE was the development of any untoward medical occurrence (other than progression of the malignancy under evaluation) in a participant or clinical study participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A SAE was an AE occurring during any study phase that fulfilled one or more of the following: resulted in death; was immediately life-threatening; required in-patient hospitalization or prolongation of existing hospitaliz
Conditions Studied
Interventions
- DRUG Durvalumab
Study Locations (20)
Other
- Research Site - Rosario
- Research Site - Box Hill
- Research Site - Melbourne
- Research Site - Brussels
- Research Site - Kortrijk
- Research Site - Leuven
- Research Site - Florianópolis
- Research Site - Ijuí
North Carolina
- Research Site - Chapel Hill
- Research Site - Huntersville
California
- Research Site - Fullerton
District of Columbia
- Research Site - Washington D.C.
Georgia
- Research Site - Augusta
Maryland
- Research Site - Baltimore
Minnesota
- Research Site - Minneapolis
Missouri
- Research Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 4 |
What the finished NCT04078152 record still lists
NCT04078152 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab is the first listed.
NCT04078152 names 20 study sites across 12 states, led by Other, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT04078152 about?
NCT04078152 is a clinical study titled "Durvalumab Long-Term Safety and Efficacy Study". The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
What is the current status of trial NCT04078152?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2019-09-05. Estimated completion is 2024-10-31.
What conditions does trial NCT04078152 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT04078152?
The interventions under investigation include: Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04078152?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04078152 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04078152's enrollment target sits among peer trials
163 53rd of 196 higher than 144 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
ACTIVE NOT RECRUITING · Phase 4
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI